Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

The Australian sharemarket closed in the red as shares fell across the region in response to the US president’s sweeping ...

Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.

In July 2025, Regeneron Pharmaceuticals organized a study is researching an experimental drug called REGN5381 (called "study ...

Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

AI-led drug for chronic lung disease set to enter phase 3 clinical trials, though experts remain divided on AI's impact in ...